Efficacy Study of Three Different Schemes of Budesonide in Recurrent Wheezing Children under 5 Years Old
- Author:
Jiang-Zhen ZHENG
1
Author Information
- Publication Type:Journal Article
- Keywords: Budesonide; Children; Modified API; Wheezing
- From: Chinese Pharmaceutical Journal 2018;53(12):1024-1028
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To explore the curative effect of the daily and two different METHODS of intermittent atomization inhalation of budesonide(BUD) in the treatment of recurrrent wheezing children under 5 years old, providing the basis for early selection of appropriate intervention regimen for them. METHODS: We studied 160 children between the aged 12 and 59 months who had positive values on the modified API(mAPI), recurrent wheezing episodes. Children were randomly divided into three groups according to admission time sequence: daily low dose atomization inhalation group (daily group) 54 cases, intermittent high dose early atomization inhalation group (early group) 53 cases and intermittent general dose preemptive atomization inhalation group (preemptive group) 53 cases. All children were observed for 1 year. Number of systemic corticosteroids courses, wheezing episodes, intravenous, the emergency number, symptomatic days, respiratory symptom scores and other curative effect indicators were compared between the three groups; and compare the number of systemic corticosteroids courses, intravenous, wheezing episodes, the emergency number, and hospitalization rates before and after treatment in each group. RESULTS: In this study, 10 children failed to complete the test because of various reasons, 150 cases were effective, each group 50 cases. All three groups can reduce the number of systemic corticosteroids courses, intravenous, wheezing episodes, the emergency number and hospitalization rate, the difference were statistically significant(P<0.01).There were no statistical significant difference between the three group in the number of systemic corticosteroids courses, wheezing episodes, intravenous, the emergency number, symptomatic days(P>0.05);there was no significant difference between the respiratory symptom scores, the number of hospitalized patients, treatment failure rate, and use SABA days of the three group (P>0.05). The BUD use days and doses of intermittent inhalation regimens is less than daily inhalation regimen(P<0.01);among the three groups, the preemptive group used the least dose(P<0.01). CONCLUSION: The efficacy of early and preemptive group is close to the daily group, and BUD days and doses of the early and preemptive group is less than that of daily group. The drug administration time of preemptive group was earlier and the overall drug delivery time is more flexible than early group, so the preemptive regimen can offer new options for 5-year-old children with recurrent wheezing and positive values on the mAPI.
